Skip to main content Skip to search Skip to main navigation

MDCG: Guidance on custom-made medical devices according to MDR

The Medical Device Coordination Group (MDCG) published an eight-page Q&A document titled Questions and Answers on Custom-Made Devices & considerations on Adaptable medical devices and Patient-matched medical devices (MDCG 2021-3) on 15 March 2021.

Ten pairs of questions and answers clarify how to deal with custom-made medical devices with regard to the new Medical Device Regulation (EU) 2017/745 (MDR).  

How are custom-made devices (CMDs) defined under the MDR?

  • They are specifically manufactured as prescribed by an authorized person under national law and based on their qualification.  
  • They have specific design characteristics provided by the responsible authorized person.  
  • They are intended for the exclusive use by a particular person to meet their individual conditions and needs.

Dental crowns, hand prostheses or orthoses are mentioned as examples.  

The Q&A clarifies the extent to which differences exist between custom-made, mass-produced and, for example, 3D-printed medical devices according to the new MDR. For example, manufacturers of "intermediates," which in turn are used to make or are combined with custom-made medical devices, must comply with MDR requirements.   

The MDCG is composed of representatives from all European member states, as well as a representative of the European Commission, who serves as chair. Thus, the Q&A is not a European Commission document and as such is not legally binding.


Source:

MDCG: Questions and Answers on Custom-Made Devices & considerations on Adaptable medical devices and Patient-matched medical devices

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

The US FDA has issued a new draft guidance (April 2026) on Impurity Specifications for Antibiotics.
Read more
EDQM: Guidance on Traceability of Medicines in Hospitals

EDQM: Guidance on Traceability of Medicines in Hospitals

The EDQM has published new guidance on the traceability of medicines in hospital settings. The aim is to improve traceability up to the point of administration and strengthen patient safety.
Read more
Which Measures are Crucial for Implementation and Monitoring of Data Integrity?

Which Measures are Crucial for Implementation and Monitoring of Data Integrity?

Here's the answer:
Read more
Contamination Control Strategy (CCS) – Not Just an Extended Site Master File

Contamination Control Strategy (CCS) – Not Just an Extended Site Master File

At the GMP-PharmaCongress in Wiesbaden, GMP inspector Frank Sielaff (Regional Authority in Darmstadt, Germany) shared practical insights from recent inspections, high-lighting deficiencies in CCS implementation.

Read more
EMA/HMA: Call for Regulatory Updates for Radiopharmaceuticals

EMA/HMA: Call for Regulatory Updates for Radiopharmaceuticals

In their „Horizon Scanning Report“, EMA and HMA have recommended updates to the regulatory framework to keep pace with developments in radiopharmaceuticals. Due to their unique characteristics these products require specific regulatory and scientific approaches.
Read more
How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

Here's the answer:
Read more
Previous
Next